US 11,773,171 B2
WNT surrogate molecules and uses thereof
Yang Li, Mountain View, CA (US); Tom Zhiye Yuan, Union City, CA (US); Aaron Ken Sato, Burlingame, CA (US); Wen-Chen Yeh, Belmont, CA (US); Claudia Yvonne Janda, Palo Alto, CA (US); Tristan William Fowler, San Francisco, CA (US); Helene Baribault, Redwood City, CA (US); Kuo-Pao Lai, Campbell, CA (US); Liqin Xie, South San Francisco, CA (US); Randall J. Brezski, South San Francisco, CA (US); and Chenggang Lu, South San Francisco, CA (US)
Assigned to Surrozen Operating, Inc., South San Francisco, CA (US)
Appl. No. 16/954,484
Filed by Surrozen Operating, Inc., South San Francisco, CA (US)
PCT Filed Dec. 19, 2018, PCT No. PCT/US2018/066616
§ 371(c)(1), (2) Date Jun. 16, 2020,
PCT Pub. No. WO2019/126398, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/680,522, filed on Jun. 4, 2018.
Claims priority of provisional application 62/641,217, filed on Mar. 9, 2018.
Claims priority of provisional application 62/607,875, filed on Dec. 19, 2017.
Prior Publication US 2020/0308287 A1, Oct. 1, 2020
Int. Cl. C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2863 (2013.01) [C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/30 (2013.01); C07K 2317/55 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 10 Claims
 
1. A soluble, multivalent, multispecific Wnt surrogate molecule, wherein the Wnt surrogate molecule comprises:
(i) one or more Fzd binding regions that specifically binds to one or more Frizzled (Fzd) receptors, wherein the one or more Fzd binding regions comprise one or more antibody or antigen-binding fragment of the antibody, wherein the one or more antibody or the antigen-binding fragment comprises: a CDRH1 of SEQ ID NO: 307, a CDRH2 of SEQ ID NO: 501, a CDRH3 of SEQ ID NO: 964, a CDRL1 of SEQ ID NO: 1098, a CDRL2 of SEQ ID NO: 1175, and a CDRL3 of SEQ ID NO: 1372; and
(ii) one or more LRP5/6 binding regions that specifically binds to a Low-density lipoprotein (LDL) receptor-related protein 5 (LRP5) and/or a Low-density lipoprotein (LDL) receptor-related protein 6 (LRP6), wherein the one or more LRP5/6 binding regions comprise one or more antibody or antigen-binding fragment of the antibody, wherein the one or more antibody or the antigen-binding fragment comprises: a CDRH1 of SEQ ID NO: 1618, a CDRH2 of SEQ ID NO: 1715, and a CDRH3 of SEQ ID NO: 2012.